Follow-Up Care for Follicular Lymphoma in Remission

Clinical Surveillance Schedule

The European Society for Medical Oncology (ESMO) guidelines recommend history and physical examination every 3 months for the first 2 years, then every 4-6 months for years 3-5, and annually thereafter, with minimal radiological imaging at 6, 12, and 24 months post-treatment in patients with follicular lymphoma in remission 1, 2
History and physical examination every 3 months with particular attention to signs of disease transformation and secondary malignancies, including new B symptoms, rapidly enlarging lymph nodes, and elevated disease markers, should be performed in the first 2 years 1, 2
Blood counts should be performed at 3, 6, 12, and 24 months, then only as clinically indicated for suspicious symptoms in patients with follicular lymphoma in remission 1, 2
Minimal radiological or ultrasound examinations should be performed at 6, 12, and 24 months after completion of treatment in patients with follicular lymphoma in remission 1, 2
History and physical examination every 4-6 months should be performed in years 3-5 post-treatment in patients with follicular lymphoma in remission 1
Annual history and physical examination should be performed beyond 5 years post-treatment in patients with follicular lymphoma in remission, with continued vigilance for transformation and secondary malignancies 1, 2

Thyroid function should be evaluated at 1, 2, and 5 years in patients who received neck irradiation 1, 2
Prophylactic antiviral medication should be continued up to 2 years beyond last rituximab exposure in patients with positive hepatitis B serology, including occult carriers 3, 4, 5

There is no established role for routine surveillance PET-CT scans during remission in patients with follicular lymphoma 3, 7, 8
PET-CT after completion of induction identifies a subset with adverse prognosis based on persistent positivity, but therapeutic consequences remain undefined 3, 7, 8
MRD analysis by PCR is an independent predictor of long-term outcome but should not guide therapeutic strategies outside clinical studies in patients with follicular lymphoma 3, 4, 5, 7, 8

A new confirmatory biopsy should be obtained at any suspected disease relapse or progression to rule out histologic transformation to aggressive lymphoma in patients with follicular lymphoma 3, 4, 5, 7, 8
Red flags requiring immediate evaluation include new B symptoms, rapidly enlarging lymph nodes, new hematopoietic impairment, and development of bulky disease or vital organ compression in patients with follicular lymphoma 3, 4, 5

Rituximab maintenance every 2 months for 2 years is recommended after first-line immunochemotherapy in patients with follicular lymphoma who achieved remission 3, 4, 5, 8
Rituximab maintenance every 3 months for up to 2 years is recommended after relapse therapy in patients with follicular lymphoma 3, 4, 5, 8